...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Chinese-German Journal of Clinical Oncology >Clinical study on concurrent chemoradiotherapy combined with Kanglaite injection in the treatment of regionally advanced unresectable non-small cell lung cancer
【24h】

Clinical study on concurrent chemoradiotherapy combined with Kanglaite injection in the treatment of regionally advanced unresectable non-small cell lung cancer

机译：同期放化疗联合康莱特注射液治疗局部晚期不可切除的非小细胞肺癌的临床研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To evaluate the clinical effects and toxicity of concurrent chemoradiotherapy combined with Kanglaite injection in the treatment of regionally advanced unresectable non-small cell lung cancer. Methods: 48 patients with regionally advanced unresectable non-small cell lung cancer were randomized to two groups, 25 patients in the combination group (concurrent chemoradiotherapy + Kanglaite) and 23 patients in the control group (concurrent chemoradiotherapy). The combination group received chemotherapy of vinorelbine (NVB) plus cisplatin (DDP) regimen, radiotherapy was given with conventional fraction in 2 Gy per fraction and five fractions per week concurrently. The total tumor doses were 56-60 Gy. Combined with Kanglaite injection 200 mL/d for twenty-one days for two courses in the combination group, the control group was chemoradiotherapy only. Effects and toxicities were evaluated according to the criteria of WHO. Results: The CR rates in the combination group and control group were 24.0% (6/25) and 13.0% (3/23), respectively (P > 0.05). Response (CR + PR) rates of combination group were 76.0 % (19/25) and 69.6% (16/23) in control group, P > 0.05. The incidence rates of grades 3-4 leukocytopenia, grades 3-4 digestive system (nausea and vomiting) and grades 3-4 esophagitis in the combination group and control group were 40.0% (10/25), 8.0% (2/25), 16.0% (4/25) and 69.6% (16/23), 34.8% (8/23), 43.5% (10/23), respectively (P < 0.05). KPS and body weight score significantly increased in combination group after the combined treatment, P < 0.05. Conclusion: Concurrent chemoradiotherapy combined with Kanglaite injection can relieve side effects of chemoradiotherapy in the treatment of regionally advanced unresectable non-small cell lung cancer, and improve quality of life. Kanglaite injection may increase effective rate of regionally advanced unresectable non-small cell lung cancer combined with concurrent chemoradiotherapy.
机译：目的：评价同期放化疗联合康莱特注射液治疗局部晚期不可切除的非小细胞肺癌的临床疗效和毒性。方法：将48例局部晚期不可切除的非小细胞肺癌患者随机分为两组，联合组25例（同期放化疗+康莱特）和对照组23例（同期放化疗）。联合治疗组接受了长春瑞滨（NVB）和顺铂（DDP）方案的化疗，放疗采用常规级分，每级2 Gy，每周同时进行5级。总肿瘤剂量为56-60 Gy。联合组在两个疗程中加用康莱特注射液200 mL / d连续21天，对照组为仅放化疗。根据世界卫生组织的标准评估效果和毒性。结果：联合组和对照组的CR率分别为24.0％（6/25）和13.0％（3/23）（P> 0.05）。对照组的反应（CR + PR）率为76.0％（19/25）和69.6％（16/23），P> 0.05。联合组和对照组的3-4级白细胞减少，3-4级消化系统（恶心和呕吐）和3-4级食管炎的发生率分别为40.0％（10/25），8.0％（2/25） ，16.0％（4/25）和69.6％（16/23），34.8％（8/23），43.5％（10/23）（P <0.05）。联合治疗后，联合治疗组的KPS和体重评分明显升高，P <0.05。结论：同时放化疗联合康莱特注射液可减轻放化疗在治疗局部晚期不可切除的非小细胞肺癌中的副作用，改善生活质量。康莱特注射液可提高局部晚期不可切除的非小细胞肺癌联合同步放化疗的有效率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号